Perivascular Renal Denervation (PVRDTM): Chemical Renal Denervation with Micro-Doses of Ethanol Using the PeregrineTM Renal Denervation Device

  • Tim A. Fischell
  • Félix Vega
  • Vartan E. Ghazarossian


In the 1930s–1950s surgical renal sympathectomy was used to treat severe hypertension [1–3]. Despite a successful lowering of blood pressure (BP) observed with surgical denervation, this technique was abandoned due to a relatively high morbidity and mortality, and as a result of the development of more effective oral antihypertensive medications


Renal Artery Renal Denervation Renal Sympathetic Denervation Refractory Hypertension Intimal Surface 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We wish to acknowledge the expert technical contributions of Jeff A. Burke, Phil C. Burke, Andy E. Denison, and Chris S. Hayden from REV-1 Engineering.

Disclosures, Conflict of Interest

TAF and VEG are principles, employees and co-founders of Ablative Solutions and have equity positions in the company. FV has is a paid consultant working with Ablative Solutions, Inc.


  1. 1.
    Harris SH. Renal sympathectomy: its scope and limitations. R Soc Med. 1935;28:1497–510.Google Scholar
  2. 2.
    Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54(6):1195–201.PubMedCrossRefGoogle Scholar
  4. 4.
    Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Investigators, SH-1. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.CrossRefGoogle Scholar
  6. 6.
    Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Kandzari DE, Bhatt DL, Sobotka PA, O’Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol. 2012;35:528–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, de Leeuw PW. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123:209–15.PubMedCrossRefGoogle Scholar
  11. 11.
    Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension. 2012;60:1479–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Ormiston JA, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT. First-in-human use of the OneShot™ renal denervation system from Covidien. EuroInterv. 2013;8:1090–4.CrossRefGoogle Scholar
  13. 13.
    Schlaich MP, Hering D, Sobotka PA, Krum H, Esler MD. Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep. 2012;14:247–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Schlaich MP, Krum H, Sobotka PA, Esler MD. Renal denervation and hypertension. Am J Hypertens. 2011;24:635–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Cook S, Goy J, Togni M. Optical coherence tomography findings in renal denervation. Eur Heart J. 2012;10:1093.Google Scholar
  16. 16.
    Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, Bertog S. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60(25):2694–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380:778.PubMedCrossRefGoogle Scholar
  18. 18.
    Virmani R. Perirenal nerve distribution, density and quantification: implications for the evaluation of device safety and efficacy. Presentation at TCT Conference, 2012, TCT 2012. p. 1–32
  19. 19.
    Fischell TA, Vega F, Raju N, Johnson ET, Kent DJ, Ragland RR, Almany ST, Fischell DR, Ghazzorossian VE. Ethanol-mediated perivascular renal denervation: preclincal validation of safety and efficacy in a porcine model. EuroInterv. 2013;9:140–7.CrossRefGoogle Scholar
  20. 20.
    Sobotka PA, Krum H, Bohm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012;14:285–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger H-R, Wirth K, et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012;60:172–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Schlaich MP, Hering D, Sobotka P, Krum H, Lambert GW, Lambert E. Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol. 2012;3:10.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168(3):2214–20.PubMedCrossRefGoogle Scholar
  27. 27.
    Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250–7.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension. 2013;61:225–31.PubMedCrossRefGoogle Scholar
  29. 29.
    Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol. 2012;101:63–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Moller JE, Helweg-Larsen J, Jacobsen E. Histopathological lesions in the sciatic nerve of the rat following perineural application of phenol and alcohol solutions. Dan Med Bull. 1969;16:116–9.PubMedGoogle Scholar
  31. 31.
    Streitparth F, Walter A, Stolzenburg N, Heckmann L, Breinl J, Rinnenthal JL. MR-guided periarterial ethanol injection for renal sympathetic denervation: a feasibility study in pigs. Cardiovasc Intervent Radiol. 2013. doi: 10.1007/s00270-013-0570-x.Google Scholar
  32. 32.
    Wali FA, Suer AH, Hayter A, Tugwell AC. The effect of ethanol on spontaneous contractions and on the contraction produced by periarterial nerve stimulation and by acetylcholine in the rat isolated ileum. Gen Pharmacol. 1987;18:631–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Kocabas H, Salli A, Demir AH, Ozerbil OM. Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. Eur J Phys Rehab Med. 2010;46:5–10.Google Scholar
  34. 34.
    Wilkes D, Ganceres N, Doulatram G, Solanki D. Alcohol neurolysis of the sciatic and femoral nerves to improve pressure ulcer healing. Pain Pract. 2009;9:145–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  • Tim A. Fischell
    • 1
    • 2
  • Félix Vega
    • 3
  • Vartan E. Ghazarossian
    • 2
  1. 1.Heart Institute at Borgess Medical CenterKalamazooUSA
  2. 2.Ablative Solutions, Inc.Kalamazoo/Menlo ParkUSA
  3. 3.San FranciscoUSA

Personalised recommendations